{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 16 of 122', 'peanut protein with no or mild symptoms. This state of desensitization is hypothesized to be', 'sufficient to protect a peanut-allergic patient in case of an accidental exposure to peanut', 'despite maintaining a peanut-avoidant diet. Although threshold exposure levels for allergic', 'reactions may vary within the peanut-allergic population, a cross-study, retrospective', 'analysis performed by the Voluntary Incidental Trace Allergen Labelling (VITAL) 2.0 study', 'group (Allen, 2014) found that 0.2 mg of peanut protein elicited an allergic reaction in 1% of', 'peanut-allergic patients and 2.1 mg of peanut protein elicited an allergic reaction in 5% of', 'peanut-allergic patients. In 1 well-documented case of accidental peanut ingestion, the', 'amount ingested was calculated to be approximately 45 mg (McKenna, 1997). More', 'recently, an observational survey conducted in France, Belgium, and Luxembourg', '(MIRABEL study) estimated the amount of food triggering an accidental allergic reaction in', '238 peanut-allergic patients. The median estimated real-life eliciting dose was', '125 mg (range, 34-177 mg) of peanut protein. The eliciting dose was < 5 mg of peanut', 'protein in 0.9% of patients, 5 to < 50 mg in 34.1%, 50 to < 100 mg in 8.3%, and > 100 mg', 'in 56.7% (Deschildre, 2016). Accordingly, desensitization to at least 300 mg of peanut protein', 'is expected to provide a clinically meaningful level of protection against most accidental', 'exposures to peanut.', '1.2', 'Summary of Relevant Clinical Experience With AR101', 'AR101 has been evaluated as a treatment for peanut allergy in more than 1000 children and', 'adults in 2 phase 2 studies (ARC001 and ARC002) and 6 phase 3 studies (ARC003,', 'ARC004, ARC007, ARC008, ARC010, and ARC011); most studies are ongoing.', '1.2.1', 'Phase 2 Studies ARC001 and ARC002', 'ARC001 was a phase 2, randomized, double-blind, placebo-controlled study of the efficacy', 'and safety of AR101 in peanut-allergic subjects aged 4 to 26 years. The intent-to-treat (ITT)', 'population included 55 subjects: 29 in the AR10 group and 26 in the placebo group. The', '2 groups were well matched overall for baseline characteristics, including baseline sensitivity', 'in the screening double-blind, placebo-controlled food challenge (DBPCFC). Subjects began', 'treatment with an initial dose-escalation phase on day 1 at 0.5 mg, dose-escalating up to', '6 mg. Subjects tolerating at least 3 mg on day 1 began up-dosing on day 2 at their maximum', 'tolerated dose (3 or 6 mg). Initial dose escalation was discontinued in subjects who could not', 'tolerate at least 3 mg of the study product. Subjects then received AR101 or placebo daily', 'for about 24 weeks, dose-escalating every 2 weeks to the target maintenance dose of', '300 mg/day. Twenty-three of 29 AR101-treated subjects (79%) reached the target', 'maintenance dose of 300 mg/day by the end of the up-dosing period and 6 subjects withdrew', 'from the study before reaching the target dose. After a 2-week maintenance period at', '300 mg/day, subjects had an exit DBPCFC with up to 600 mg (1043 mg cumulative) of', 'peanut protein or placebo (oat flour). All 23 AR101-treated subjects tolerated at least', '300 mg (443 mg cumulative) of peanut protein with no more than mild symptoms during the', 'exit DBPCFC, compared with 5 of 26 subjects in the placebo group, resulting in a treatment', 'difference of 60% (p < 0.0001 by Fisher exact test). Further, 18 AR101-treated subjects', '(62%) tolerated 600 mg (1043 mg cumulative) of peanut protein during the exit DBPCFC,']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 17 of 122', 'compared with none in the placebo group, resulting in a treatment difference of 62%', '(p < 0.0001 by Fisher exact test) (Bird, 2018; AR101 investigator brochure).', 'The open-label follow-on study ARC002 evaluated the safety and efficacy of AR101 in', '47 eligible peanut-allergic subjects who participated in the ARC001 originating study.', 'Former placebo-treated subjects began AR101 up-dosing to 300 mg/day, followed by', '2 weeks of daily dosing at 300 mg/day and a post-up-dosing DBPCFC. At the', 'post-up-dosing DBPCFC, former placebo-treated subjects exhibited a high rate of', 'desensitization, with 20 of 21 subjects (95%) tolerating the 300 mg (443 mg cumulative)', 'dose of peanut protein. No moderate or severe adverse events were reported and no subject', 'required epinephrine. These findings are consistent with those of the originating study exit', 'DBPCFC in AR101-treated subjects. A total of 40 subjects overall, in both the former', 'placebo-treated and AR101-treated groups, began a 12-week maintenance period at', '300 mg/day, followed by a DBPCFC. The DBPCFC was considered passed if the subject', 'tolerated at least 300 mg of peanut protein with no or mild symptoms. Of the 40 subjects', 'overall, 100%, 90%, and 60% of the subjects tolerated a peanut protein dose of 300 mg', '(443 mg cumulative), 600 mg (1043 mg cumulative), and 1000 mg (2043 mg cumulative),', 'respectively. Moderate or severe adverse events were reported in a minority of subjects at', 'the 2 highest doses. Two subjects each required a single dose of epinephrine (Bird, 2016;', 'AR101 investigator brochure).', 'The results from these phase 2 AR101 studies demonstrate the persistence of desensitization', 'during maintenance treatment with AR101 at 300 mg/day and indicate that treatment with', 'AR101 may result in a substantially higher tolerated dose of peanut allergen than the dose', 'used for maintenance. Further, desensitization to 300 to 600 mg of peanut protein, the', 'equivalent of approximately 1 to 2 whole peanut kernels (Baumert, 2017), is clinically', 'relevant and expected to reduce the risk of allergic reaction to most accidental exposures to', 'peanut.', '1.2.2', 'Phase 3 Pivotal Study ARC003', 'ARC003 was an international, randomized, double-blind, placebo-controlled phase 3 study of', 'the efficacy and safety of AR101 in a CODIT regimen in peanut-allergic children and adults', 'aged 4 to 55 years. Preliminary analysis of the final study data is in progress for the database', 'locked in January 2018. Of total of 554 subjects enrolled, 499 subjects were aged 4 to', '17 years. The ITT population for the primary analysis included 496 subjects aged 4 to', '17 years (372 in the AR101 group and 124 in the placebo group); 67.2% of AR101-treated', 'subjects tolerated a single highest dose of at least 600 mg of peanut protein (1043 mg', 'cumulative) with no more than mild symptoms in the exit DBPCFC compared with 4.0% of', 'placebo-treated subjects, resulting in a treatment difference of 63.2% (p < 0.0001;', '95% CI: 53.0, 73.3). In addition, 50.3% of AR101-treated subjects tolerated a single highest', 'dose of 1000 mg of peanut protein (2043 mg cumulative), compared with 2.4% of', 'placebo-treated subjects (p < 0.0001; 95% CI: 38.0, 57.7). Of subjects aged 4 to 17 years,', '296 AR101-treated subjects and 116 placebo-treated subjects had an evaluable exit DBPCFC', '(completer population). A single highest dose of peanut protein was tolerated with no more', 'than mild symptoms in the exit DBPCFC by 96.3% of AR101-treated completers versus', '8.6% of placebo completers for at least 300 mg (443 mg cumulative), 84.5% versus 4.3% for']\n\n###\n\n", "completion": "END"}